Literature DB >> 28130288

Topical timolol for the treatment of pyoderma gangrenosum.

Catarina Moreira1,2, Sofia Lopes1, Maria João Cruz1,2, Filomena Azevedo1.   

Abstract

Treatment of pyoderma gangrenosum (PG) remains a challenge, and there are currently no specific or uniformly effective therapies. Although widespread or rapidly progressive disease often requires systemic treatment, localised and mild lesions may be effectively controlled with topical agents. The most frequently applied topical drugs are corticosteroids and calcineurin inhibitors. Recently, a patient with idiopathic PG of the lower limb was successfully treated with topical timolol and collagenase. Here, we report a case of a patient with collagenous colitis, ankylosing spondylitis and periumbilical PG. Persistent ulcerated skin lesions were successfully treated with topical timolol, although a flare of the underlying bowel disease temporarily interrupted the improvement. The case presented enhances the previously reported therapeutic potential of topical timolol in the treatment of PG. Control of chronic underlying disorders is critical to prevent rebound flares and maintain the benefit. 2017 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28130288      PMCID: PMC5278339          DOI: 10.1136/bcr-2016-218589

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

1.  Topical timolol for a refractory wound.

Authors:  Jennifer C Tang; Jacquelyn Dosal; Robert S Kirsner
Journal:  Dermatol Surg       Date:  2011-10-31       Impact factor: 3.398

2.  Successful treatment of a chronic venous leg ulcer using a topical beta-blocker.

Authors:  Hadar Lev-Tov; Sara Dahle; Joyce Moss; Roslyn R Isseroff
Journal:  J Am Acad Dermatol       Date:  2013-10       Impact factor: 11.527

3.  Topical timolol for recalcitrant wounds.

Authors:  Liza R Braun; Sonia A Lamel; Nicholas A Richmond; Robert S Kirsner
Journal:  JAMA Dermatol       Date:  2013-12       Impact factor: 10.282

4.  Collagenase ointment and topical timolol gel for treating idiopathic pyoderma gangrenosum.

Authors:  Deede Y Liu; Ryan Fischer; Garth Fraga; Daniel J Aires
Journal:  J Am Acad Dermatol       Date:  2014-10-15       Impact factor: 11.527

5.  Topical Timolol for Infantile Hemangiomas: Evidence for Efficacy and Degree of Systemic Absorption.

Authors:  Lisa Weibel; Marjam J Barysch; Helene S Scheer; Ingo Königs; Kathrin Neuhaus; Clemens Schiestl; Katharina Rentsch; Daniel M Müller; Martin Theiler
Journal:  Pediatr Dermatol       Date:  2016-02-03       Impact factor: 1.588

Review 6.  Pyoderma gangrenosum: challenges and solutions.

Authors:  Ana Gameiro; Neide Pereira; José Carlos Cardoso; Margarida Gonçalo
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-05-28

7.  Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study.

Authors:  Kim S Thomas; Anthony D Ormerod; Fiona E Craig; Nicola Greenlaw; John Norrie; Eleanor Mitchell; James M Mason; Graham A Johnston; Shyamal Wahie; Hywel C Williams
Journal:  J Am Acad Dermatol       Date:  2016-08-05       Impact factor: 11.527

  7 in total
  3 in total

1.  Pyoderma gangrenosum: From historical perspectives to emerging investigations.

Authors:  Misty M Hobbs; Alex G Ortega-Loayza
Journal:  Int Wound J       Date:  2020-05-06       Impact factor: 3.315

Review 2.  Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments.

Authors:  Carlo Alberto Maronese; Matthew A Pimentel; May M Li; Alex G Ortega-Loayza; Angelo Valerio Marzano; Giovanni Genovese
Journal:  Am J Clin Dermatol       Date:  2022-05-24       Impact factor: 6.233

Review 3.  Topical beta-blockers in dermatologic therapy.

Authors:  Angela Filoni; Francesca Ambrogio; Aurora De Marco; Alessia Pacifico; Domenico Bonamonte
Journal:  Dermatol Ther       Date:  2021-06-21       Impact factor: 2.851

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.